Stock price when the opinion was issued
Private equity (used to be called leveraged buyouts). An American version of Brookfield is a way to conceptualize it. Manage $640B of private equity. Organic growth bolstered by recent acquisition, which takes them into insurance and annuities. Rapidly growing capital markets business. Secular advantage of private market flows are outpacing public market flows. Yield is 0.6%.
(Analysts’ price target is $168.67)He looks at relative strength, head-to-head battles and who's winning. As money flew out of financials, he sold his position. Big correction at the beginning of February. Picked up support ~$110, similar to the August low. Starting to come back. If it can break out above the trend line ~$125, looks encouraging.
Yes, if you can handle the ride. No, if you can't. When Trump was elected last November on promises of market regulation, these stocks ripped. Then, tariffs hit, and KKR shares plunged. You can nibble at it here at these lows.
With interest rates not coming down as fast as expected, and with volatility in the market, there are concerns about its deal-making ability. Expects to see a lot of liquid products over the next 1-2 years from this name and its peers. Headwinds from tariffs and regulations, but those are dissipating at the moment.
Doesn't really have an opinion on KKR. The love of his life is BN, and they've owned it for quite a long time. Likes that it collects giant fees from diversified assets. His preferred play on alternative assets.
Global, leading asset manager in private market alternatives. AUM has grown at 18% compound pace, which gives them recurring management fee revenue. Also gets a share of profits on portfolios they manage. Acquired an insurance/annuity company in 2024 to smooth out volatility of private market businesses.
(Analysts’ price target is $164.00)About 8-10% off January highs. Catch-up trade is very likely. Yield is 0.50%.